Hetrombopag Olamine

Summary

Hetrombopag Olamine (CHEMBL4297764) is a phase-3 clinical-stage unknown; indicated across 4 conditions including aplastic anemia and autoimmune thrombocytopenic purpura.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 4 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297764
Name	Hetrombopag Olamine
Type	Unknown
Max phase	3

Also known as: Hetrombopag diolamine, Hetrombopag ethanolamine, Hetrombopag olamine, Rafutrombopag olamine, SHR-8735 OLAMINE, SHR8735 OLAMINE, HETROMBOPAG OLAMINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
aplastic anemia	3	MONDO:0015909	EFO:0006927
autoimmune thrombocytopenic purpura	3	MONDO:0008558	EFO:0007160
thrombocytopenia	2	MONDO:0002049	HP:0001873

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE1	6
PHASE3	4
PHASE2	3
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05575986	PHASE4	UNKNOWN	Herombopag Olamine in the Treatment of Thrombocytopenia After Chemotherapy
NCT04961710	PHASE3	ACTIVE_NOT_RECRUITING	Extension Study of Hetrombopag in Severe Aplastic Anemia
NCT07286032	PHASE3	RECRUITING	A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
NCT03222843	PHASE3	COMPLETED	Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient
NCT03825744	PHASE3	COMPLETED	Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
NCT05944211	PHASE2	NOT_YET_RECRUITING	Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia
NCT06433830	PHASE2	RECRUITING	Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy
NCT06478537	PHASE2	RECRUITING	TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
NCT03557099	PHASE1/PHASE2	COMPLETED	A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient
NCT01830660	PHASE1	COMPLETED	A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers
NCT02403440	PHASE1	UNKNOWN	A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT02409394	PHASE1	COMPLETED	Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects
NCT02614846	PHASE1	UNKNOWN	Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT03603132	PHASE1	COMPLETED	A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics
NCT03977805	PHASE1	COMPLETED	Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).